Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against NIO, Indivior, Boston Scientific, and KushCo and Encourages Investors to Contact the Firm

NEW YORK, May 06, 2019 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of NIO Inc., Indivior PLC, Boston Scientific Corporation, Inc., and KushCo Holdings, Inc.  Stockholders have until the deadlines listed below to petition the court to serve as lead plaintiff.  Additional information about each case can be found at the link provided.

NIO Inc. (NIO)

Class Period:   September 12, 2018 - March 5, 2019

Lead Plaintiff Deadline: May 13, 2019

The complaint alleges that throughout the class period defendants made false and/or misleading statements and/or failed to disclose that: (1) NIO would not be building its own manufacturing plant and would instead continue to rely on a little-known Chinese state-owned auto manufacturer, JAC Auto, to manufacture its electric vehicles; (2) reductions in government subsidies for electric cars would materially impact NIO’s sales; and (3) as a result, defendants’ statements about NIO’s business, operations, and prospects were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To learn more about the NIO class action go to: http://bespc.com/nio/.

Indivior PLC (Other OTC: INVVY)

Class Period: March 10, 2015 - April 9, 2019

Lead Plaintiff Deadline: June 24, 2019

The complaint alleges that during the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) Indivior and its executives engaged in an illicit nationwide scheme to increase prescriptions of Suboxone Film; (2) Indivior illegally obtained billions of dollars in revenue from Suboxone Film prescriptions by deceiving health care providers and health care benefit programs; (3) as a result of the aforementioned misconduct, Indivior would face felony charges; and (4) due to the foregoing, defendants’ statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times. 

To learn more about the Indivior class action go to: http://bespc.com/invvy/.

Boston Scientific Corporation (BSX)

Class Period: February 26, 2015 - April 16, 2019

Lead Plaintiff Deadline: June 24, 2019

The complaint alleges that during the Class Period defendants made materially false and misleading statements regarding the company’s business, operational and compliance policies.  Specifically, the complaint alleges that defendants made false and/or misleading statements and/or failed to disclose that:  (1) Boston Scientific’s surgical mesh products indicated for the transvaginal repair of POP were unsafe; (2) accordingly, Boston Scientific’s continued marketing and sales of these devices in the United States was unlikely to be sustainable; (3) separately, the company had sold vaginal mesh implants containing counterfeit or adulterated resin products imported from China; (4) the foregoing conduct subjected the company to a heightened risk of regulatory scrutiny and/or government investigations; and (5) as a result, the company’s public statements were materially false and misleading at all relevant times.

To learn more about the Boston Scientific class action go to: http://bespc.com/bsx/.

KushCo Holdings, Inc. (Other OTC: KSHB)

Class Period: July 13, 2017 - April 9, 2019

Lead Plaintiff Deadline: July 1, 2019

The complaint alleges that throughout the class period defendants made materially false and misleading statements regarding the company’s business, operational and compliance policies.  Specifically, the complaint alleges that defendants made false and/or misleading statements and/or failed to disclose that: (1) KushCo made material accounting errors in connection with its acquisitions of CMP Wellness, Summit, and Hybrid; (2) as a result, KushCo’s previously issued financial statements as of and for the fiscal years ended August 31, 2018 and August 31, 2017, included in the company’s Annual Reports on Form 10-K for such periods, and financial statements as of and for the quarterly periods ended May 31, 2017, November 30, 2017, February 28, 2018, May 31, 2018 and November 30, 2018, included in the company’s Quarterly Reports on Form 10-Q for such periods, could not be relied upon; (3) KushCo’s net loss for the fiscal year ended August 31, 2018, was more than twice as high than previously reported; (4) KushCo and its management’s assurances that its financial statements for those fiscal years and periods were accurate and fairly reported could not be relied upon; and (5) as a result, the company’s public statements were materially false and misleading at all relevant times.